A Phase 1 Study of the Relative Bioavailability of Two PRN1008 Tablet Formulations, Effect of PRN1008 on Midazolam Pharmacokinetics, and Impact of Famotidine on PRN1008 Pharmacokinetics in Healthy Subjects

Trial Profile

A Phase 1 Study of the Relative Bioavailability of Two PRN1008 Tablet Formulations, Effect of PRN1008 on Midazolam Pharmacokinetics, and Impact of Famotidine on PRN1008 Pharmacokinetics in Healthy Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs PRN 1008 (Primary) ; Famotidine; Midazolam
  • Indications Autoimmune disorders; Idiopathic thrombocytopenic purpura; Pemphigus vulgaris
  • Focus Pharmacokinetics
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top